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Abstract: Pituitary adenomas are benign pituitary primary tumors, the most frequent 
type of tumor in the pituitary fossa. An important part, around 1/3 of the pituitary 
adenomas manifests an aggressive behavior, growing faster and invading into parasellar 
areas (cavernous sinus, neural tissues and bones). Objectives: the first aim of this paper 
is to review the last findings about invasiveness diagnostic criteria, imagistic and 
biomarkers, which can be used in the classification of pituitary tumors and also to predict 
the probability of invasiveness, tumor recurrence and suspicion of malignancy. The 
second aim is to highlight the morphological and clinic types of invasive pituitary 
adenomas. Materials and methods: we performed a systematic review and analysis of the 
published articles, searching PubMed between January 1985 and December 2015. There 
were selected articles published in English, reviews and abstracts. During the advanced 
search type in PubMed, combinations of the following keywords were used: “pituitary 
adenoma”, “invasive”, “aggressive”, “biomarkers”, “classification”, “histological 
subtypes”, ‘”immunohistochemical markers”. Results: 215 articles were selected, 
regarding diagnostic, prognostic and therapeutic aspects. There were some histological 
subtypes of pituitary adenomas known as having an aggressive clinical behavior. Several 
biomarkers were identified as being associated with the invasive feature: proliferation 
markers (Ki-67 index, number of mitoses, p53 & p27 expression, microvascularization 
density, telomerase, topoisomerase 2 Alpha), matrix metalloproteinases, protein kinase 
C, cyclooxygenase-2, E-cadherin, transcription Factors, genetic alterations (PTTG gene, 
Galectin-3 protein/ LGALS3 gene), apoptosis markers. Based on their invasion and 
proliferation characteristics, pituitary tumors are proposed to be classified into five 
grades (1a, 1b, 2a, 2b, 3), the grade 2b tumor with high risk of recurrence being 
considered as tumor suspected of malignancy. Conclusions: Using a set of specific 
biological markers for invasive process, there is hope to establish an early diagnosis and 
prevention of invasive pituitary adenomas. Due to the fact that aggressive pituitary 
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tumors are generally difficult to manage, unresponsive to therapy, quickly recurrent and 
associated with poor prognosis, the early diagnosis and the search for new therapeutic 
approaches is becoming mandatory. Instead of using “invasive” or “aggressive” 
adenoma, the term “tumor suspected of malignancy” would be used for more accuracy. 
Key words: pituitary adenoma, invasive, aggressive, biomarkers, classification, 
histological subtypes, immunohistochemical markers 
 
Introduction 
The pituitary primary tumors, originating 
from adenohypophyseal cells, can be benign 
(adenomas) and malignant (carcinomas). 
The pituitary adenomas’ incidence is about 
10–15% of all brain tumors, being on the third 
place, after gliomas and meningiomas. The 
pituitary carcinomas represent only 0.1% of all 
pituitary tumors (1).  
Invasion represents the phenomenon in 
which the cells from a malignant neoplasm 
extend to the adjacent healthy tissues, 
infiltrating and destructing them. For 
epithelial neoplasms, invasion signifies 
infiltration beneath the epithelial basement 
membrane. Although pituitary adenomas are 
non-metastasizing tumors, invasive local 
growth occurs in 35% of cases (2).  
Atypical adenomas are small subset of 
pituitary adenomas, tumors with a more 
aggressive behavior, which have potential to 
grow faster than typical adenoma and have 
also potential of invasion into vascular 
(cavernous sinus), neural tissues and bones 
(1).   
Most of the neurosurgeons agree that a key 
feature in defining an ‘‘aggressive’’ pituitary 
tumor is the rapidity of growth, which often 
may cause an early recurrence. A tumor that 
re-grow in 6 months is considered 
‘‘aggressive’’, compared with a recurrence in 
10 years after a complete resection, which 
might be considered as a benign behavior (2).  
Materials and methods 
An extensive medical literature research 
was performed in Pubmed, years of 
publication from January 1985 – December 
2015. The analyzed articles were published in 
English language, in abstract or in extenso and 
20 articles were excluded. There were selected 
articles focusing on classification of pituitary 
tumors, biomarkers of invasiveness, diagnostic 
criteria, morphologic types of invasive 
pituitary tumors, imagistic criteria, on tumor 
recurrence and suspicion of malignancy. 
For the research, there were used 
combinations of 2 or 3 of the biomarkers 
identified as being associated with the invasive 
feature: proliferation markers (Ki-67 index, 
number of mitoses, p53 & p27 expression, 
microvascularization density, telomerase, 
topoisomerase 2 Alpha), matrix 
metalloproteinases, protein kinase C, 
cyclooxygenase-2, E-cadherin, transcription 
Factors, genetic alterations (PTTG gene, 
Galectin-3 protein/ LGALS3 gene), apoptosis 
markers. 
Results 
From clinical point of view, in the studied 
articles was found that the pituitary tumors are 
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classified into functioning – acromegaly 
syndrome with growth hormone (GH) 
secretion, or amenorrhea-galactorrhea with 
prolactin (PRL) secretion, or Cushing’s disease 
with adrenocorticotropic hormone (ACTH) 
secretion) and nonfunctioning tumors – 
secreting mainly follicle-stimulating hormone 
(FSH) and luteinizing hormone (LH). The 
functional tumors represent 75% of pituitary 
adenomas, but the non‑secreting tumors are 
usually larger (3). 
Beside the increased secretion of some 
hormones, the pituitary tumors are usually 
causing a subsequent “mass effect” on 
surrounding structures (optic chiasm and/or 
the cavernous or sphenoid sinuses), with 
symptoms and signs such as: headaches; 
epistaxis (due to downward extension through 
the floor of sella) (4); visual field impairment 
(typically bi‑temporal field loss or diplopia) or 
even proptosis (due to a mass extended to 
orbit) or other neurological deficits (cranial 
nerve palsies, due to invasion into cavernous 
sinus) (4). Headaches or vision loss with 
sudden onset can be due to hemorrhage or 
necrosis of tumor (5). 
In the studied articles we identified several 
hormone-secreting and morphological 
subtypes of pituitary adenomas, which tend to 
have a more aggressive clinical behavior. 
These include: 1) aggressive prolactin-
secreting pituitary tumors (sparsely 
granulated somatotroph  and acidophil stem 
cell adenomas); 2)  aggressive corticotroph 
pituitary tumors (silent corticotroph 
adenomas, thyrotroph adenomas, Crooke’s 
cell adenomas); 3) aggressive growth-
hormone secreting pituitary tumors(more 
common are densely and sparsely granulated 
somatotroph adenomas); 4) aggressive 
gonadotroph and thyrotroph pituitary tumors 
(tumors immunohistochemical positives for 
the FSH and/or LH gonadotrophins or the 
oncocytomas); and 5) aggressive 
plurihormonal tumors (silent subtype 3 
adenomas).   
Tumor invasion was defined based on one 
or more of the following parameters: 
preoperative imaging (MRI or CT), 
intraoperative findings, and histology (6). By 
size, pituitary adenomas are classified by size 
into microadenoma (b<10 mm) and 
macroadenomas (≥10 mm).  
It was shown that the invasion of the 
cavernous sinus space occurs in 6 to 10% of all 
pituitary adenomas. It is only considered an 
unequivocal invasion of the cavernous sinus, 
when the percentage of encasement of the 
internal carotid artery by the tumor is 67% or 
greater, or for grades 3 or 4 of Knosp’s 
classification (7). In case of such large invasive 
macroadenoma, the total surgical resection is 
unobtainable. 
The proliferation markers for aggressive 
pituitary tumorsidentified were: Ki-67 index, 
number of mitoses, p53 & p27 expression, 
microvascularization density, telomerase, 
topoisomerase 2 Alpha. The main diagnostic 
criteria for atypical pituitary adenoma, 
included in all the studied articles, included: 
pleomorphism, elevated mitotic index, 
increased nuclear reaction for the p53 protein, 
and a Ki-67 proliferative index >3% (8).  
Increasing levels of Ki-67 correlate with 
rate of tumor growth, invasion, responsiveness 
to pharmacological treatment, tumoral 
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remission and recurrence (8). A threshold of 
3% Ki-67 index can distinguish between 
invasive and noninvasive adenomas, with 97% 
specificity and 73% sensitivity and has indeed 
a prognostic value (9). The mean values of Ki-
67, reported by Thapar et al. (1996) were 
1.37% in noninvasive pituitary adenomas, 
4.66% in invasive adenomas and 11.91% in 
carcinomas (9).  
A number of mitoses higher than 2/10 
HPFs (10 HPF: high power field=2 mm2, at 
least 40 fields, at 40× magnification, evaluated 
in areas of highest mitotic density) indicate the 
proliferative characteristic of a tumor (10).  
Several studies showed an increased p53 
expression in ‘aggressive-invasive’ pituitary 
tumors: significantly higher (p=0.0001) or of 
15% in invasive pituitary adenomas and of 
100% in pituitary carcinoma metastases (11, 
12).  
p27 KIP1 expression was found lower in 
recurrent adenomas compared with non-
recurrent ones, especially in corticotroph 
adenomas, and in carcinomas compared with 
invasive adenomas (13). 
In invasive pituitary tumors Vidal et al. 
described a higher microvascular density, but 
without statistical significance (14). Also, 
Salehi et al. obtained inconsistent association 
between the expression of vascular endothelial 
growth factor (VEGF) and the tumor 
invasiveness and proliferation (15). 
Harada et al. (16) and Yoshino et al. (17) 
detected a telomerase expression in 13% of 
large, invasive adenomas, therefore telomerase 
detection may be also useful for identifying 
aggressive adenomas.   
Also, in pituitary adenomas, there were 
reported low values of topoisomerase II alpha, 
results similar to those of Ki-67, however 
further studies are requested to establish if this 
enzyme is a valid marker of tumor 
aggressiveness (18). 
Other characteristics modifications in 
aggressive pituitary tumors identified in the 
studied articles were: matrix 
metalloproteinases, protein kinase C (PKC), 
cyclooxygenase-2, E-cadherin, genetic 
alterations (PTTG gene, Galectin-3 protein/ 
LGALS3 gene), apoptosis markers. 
In aggressive/invasive pituitary tumors, it 
was demonstrated that MMP9 expression level 
and activity is higher than in noninvasive 
pituitary tumors (19).  
In invasive pituitary adenomas was shown 
by a point mutation of PKC-α and a higher 
total PKC activity and expression (20) and in 
some cases of prolactinomas that responded 
favorably to dopamine agonists therapy was 
observed a reduced PKC activity.  
Cyclooxygenase-2 (COX-2) presents an 
increased expression evident particularly in 
pituitary carcinomas, compared with 
adenomas and normal pituitary (21), 
In a study of van Roy and Berx it was 
observed that in pituitary aggressive/invasive 
adenoma, cells E-cadherin and β-catenin 
expression was downregulated and a 
decreased E-cadherin expression can lead to 
development of metastases (22).  
Also, they were demonstrated 
accumulations of new chromosomal 
alterations which may transform an 
“aggressive” pituitary tumor into a pituitary 
carcinoma, as in the case of PRL aggressive 
tumors (grade 2b), that became malignant and 
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developed metastasis during follow-up (the 
11p region was usually deleted, the 11q arm 
was loss and in the 1q arm was a gain) (23).  
Zhang et al. noted significantly higher 
levels of pituitary tumor transforming gene 
(PTTG) expression in hormone-secreting 
invasive tumors compared with non-invasive 
ones (24). 
In both PRL and ACTH functioning 
pituitary tumors (adenomas and carcinomas) 
was shown that LGALS3 has a higher 
expression, with the highest level in ACTH 
carcinomas (25). 
Higher apoptotic activity was reported in 
aggressive, drug-resistant adenomas by 
Kontogeorgos et al. (26) and in pituitary 
carcinomas compared with adenomas, Kulig 
et al. (27) reported a four-fold increase in 
apoptotic activity.  
Discussions 
Imagistic diagnostic criteria for aggressive 
pituitary tumors 
Recent anatomical and ultrastructural 
studies have shown that the medial wall of the 
cavernous sinus is composed of dura. Dural 
invasion is not considered a feature of invasion 
because previous studies demonstrated that it 
is not related to the recurrence rate. 
Suprasellar growth is considered an extension, 
rather than an invasion. According to Hardy’s 
neuroradiological classification, tumors with a 
suprasellar expansion that were frequently 
lined by non-tumoral pituitary, are not 
considered as invasive.  
Any tumor growth into the cavernous 
sinus would therefore represent a sign of 
invasiveness without histological proof, such 
as the invasion into the sphenoid sinus 
confirmed by the infiltrated respiratory 
mucosae on histology.   
New methods of immunohistochemistry, 
by staining with KI-67, a significantly higher 
proliferation rate were demonstrated in 
invasive adenomas; this was not only true in 
pituitary adenomas with histologically proven 
invasion of the dura, but also in pituitary 
adenomas macroscopically invading the 
cavernous sinus space (28).  
MRI importance 
MRI offers detailed information on the 
anatomical relationship of the tumor with the 
surrounding structures; therefore, it is 
considered as the method of choice in the 
diagnosis of pituitary adenomas and it also 
become the gold standard for diagnosis and 
follow-up of pituitary adenomas. The 
application of gadolinium-
diethylenetriaminepentaacetic acid (Gd-
DTPA) enhances precisely the cavernous 
venous plexus, which allow the precise 
distinction between the medial, superior, 
inferior, and lateral compartments (29).  
Although it is common to wait 3–4 months 
after surgery to obtain the first MRI, even 
immediate postoperative imaging is useful to 
provide information regarding the presence of 
residual tumor, in order to start early specific 
therapeutic strategies. 
But despite the MRI improvements, there 
are authors who consider that the invasion 
into the cavernous sinus space cannot be 
proved only by MRI and that the invasion of 
the cavernous sinus space remains a surgical 
diagnosis, because only the surgeon can 
distinguish between compression of the 
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venous spaces and real infiltration of the 
medial wall of the cavernous sinus space (30). 
Proliferation markers for aggressive 
pituitary tumors 
There are evidences at the molecular level 
which indicate that pituitary tumors 
accumulate abnormalities over time, fact that 
contribute to their progression from ‘‘benign’’ 
adenoma to aggressive recurrent pituitary 
tumors and even to a pituitary carcinoma (15).  
Proliferation is defined as the presence of at 
least two of the three markers: mitoses or Ki-
67 index which exceeded the defined 
thresholds, or positive p53 detection.  
Ki-67 index 
The protein Ki-67 is a marker of cell 
proliferation present in the nuclei of cells in 
G1, S, and G2 cell division cycle phases and in 
mitosis. The Ki-67 expression is detected by 
the monoclonal antibody MIB-1 and is 
quantified as Ki-67 proliferation index being a 
percentage of immunopositive nuclei (31). 
The Ki-67 index >1 or C3% according to 
the Bouin-Hollande or formalin fixative and 
the number of mitoses n>2/10 HPFs had been 
defined previously in pituitary and/or 
endocrine tumors (10). For pituitary 
adenoma, Ki-67 is a routinely examined 
marker of cell proliferation. 
In clinical practice, Ki-67 index is daily 
used to select the patients who need a strict 
follow-up, because a very high proliferation 
index suggests the presence of a carcinoma in 
situ or premetastatic carcinoma, with potential 
for a rapidly progressive and fatal course. The 
above mentioned data have led to a proposal 
that pituitary tumors exhibiting Ki-67 index 
greater than 10% should routinely be classified 
as atypical independent of other criteria (21).  
Even if Ki-67 index >3% is considered a 
good proliferation marker, its values exhibit a 
certain variability. They vary depending of 
immunohistochemical (IHC) type and in 
functional pituitary tumors are higher than in 
nonfunctioning ones. Also, there are authors 
who found no correlation between Ki-67 index 
and pituitary tumor invasiveness (21). 
Therefore, it is recommended the use of other 
makers for more accurate prediction of the 
tumor behavior. 
Number of mitoses 
Beside Ki-67 index, also the presence and 
the number of mitoses can represent 
important predictive factors of proliferation 
and rapid growth in endocrine tumors. 
p53 expression  
p53 is a tumor suppressor gene that plays 
an important role in cell proliferation, 
apoptosis and genomic stability. There are also 
reports about a non-conclusive correlation 
between p53 increased expression and 
aggressive adenoma behavior (31), but it is 
possible to exist differences in p53 evaluation 
between laboratories and pathologists. 
Therefore, only the p53 positivity or negativity 
is considered, because, actually, there is no 
validated prognostic cut-off for it (11), but a 
p53 positive immune reaction has been found 
in all pituitary carcinomas (9,11) and, also, p53 
is one of the criteria to classify ‘‘atypical 
adenomas’’ (6).  
p27 expression  
p27 KIP1 is a cyclin-dependent kinase 
inhibitor, involved in regulation of cell-cycle 
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progression.Because p27 KIP1 expression was 
inversely correlated with the Ki-67’s one, it 
was suggesting that p27 KIP1 is an additional 
predictive marker of pituitary tumor behavior 
(32). 
Telomerase  
Telomerase is a reverse transcriptase 
enzyme carrying its own RNA molecule, 
which elongates telomeres and contributes to 
the preservation of the senescence-crisis-
apoptosis cycle. Because this represent one of 
the fundamental defense mechanisms against 
cancer development, this can be a valuable 
exploration in aggressive pituitary tumors.  
Topoisomerase 2 Alpha 
Topoisomerase II alpha is a key enzyme 
involved in DNA replication and cell-cycle 
progression, not found in resting cells; its 
expression correlates with cell proliferation 
(18), fact which can also be valuable in 
exploring aggressive tumor comportment.  
Other characteristics modifications in 
aggressive pituitary tumors 
Angiogenesis 
The “angiogenic switch”, the imbalance 
between stimulating and inhibiting 
angiogenetic factors, becoming predominant 
promoting factors, represents an important 
phenomenon in tumorigenesis: the formation 
of new blood vessels sustains the tumor 
growth. 
It was observed that in pituitary adenomas, 
they are less vascularized than the normal 
pituitary tissue; this can explain the slow 
growth and lack of metastasis, and lead to the 
development of the hypothesis that pituitary 
adenoma evolve through a non-angiogenic 
pathway. In carcinomas it was observed a 
higher vascularization than in the adenomas, 
finding which supports the idea that the 
development of metastasis is correlated with 
the neo-angiogenesis (33).  
But nevertheless, VEGF is an important 
angiogenic factor up-regulated by PTTG and 
future studies could confirm its link with 
invasive pituitary adenomas (15). 
Other enzymes  
Matrix metalloproteinases 
The matrix metalloproteinases (MMP) are 
a family of proteolytic enzymes cleaving the 
extracellular matrix molecules. MMPs play a 
role in invasiveness of many neoplasms and 
the MMP study underlines the importance of 
the pituitary tumor environment. 
The expression of MMP9 may be 
correlated with the activation of protein kinase 
C (PKC), which is also known to indicate 
invasion and aggressive behavior of pituitary 
tumors (34). 
Protein kinase C 
PKC is a ubiquitous family ofisoform 
enzymes, playing important roles in 
controlling the function of other proteins and 
in signal transduction cascades. Therefore, 
PKC are associated with a variety of cellular 
responses, including cell growth and invasion 
(19). 
PKC activation has been shown to increase 
MMP-9 expression in some tumor cells. 
Because PKC activates MMP-9 in a highly cell-
type-specific manner, the differential 
expression of PKC isozymes may involve 
various signal transduction pathways; 
therefore, it is important to identify which 
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PKC isozyme is regulating the MMP-9 
expression of in pituitary adenomas (19). 
Cyclooxygenase-2 
COX-2 is a key enzyme of prostaglandin 
synthesis, involved in inflammatory responses. 
There were studies who reported that COX-2 
presents an increased expression also in the 
gonadotrophic tumors, compared with other 
pituitary neoplasms (35). The observations 
sustain the COX-2 implication in tumor 
invasiveness, angiogenesis and progression; 
indeed, it was observed that COX-2 expression 
shows a strong correlation with microvessel 
density (21). 
E-Cadherin  
E-cadherin is a calcium-dependent cell 
adhesion protein, playing an important role in 
epithelial cell behavior and tissue development 
and having a strong anti-invasive and anti-
metastatic role. In normal pituitary cells E-
cadherin is strongly expressed (22).  
Transcription Factors/regulators 
For immunonegative or silent tumors, the 
transcription factors involved in pituitary cell 
differentiation may be used to confirm the 
diagnosis. Pit-1 is expressed in GH, PRL, and 
thyroid stimulating hormone (TSH) tumors; 
T-pit in ACTH tumors with and without 
Cushing’s disease and SF-1 in FSH and LH 
tumors (36).  
Rarely, some pituitary tumors differentiate 
functionally and produce hormones belonging 
to different cell lineages (ACTH-omas with 
GH production, or GH-omas with ACTH 
production); this abnormal differentiation 
could be caused by an aberrant expression of 
transcription factors (37).  
Ikaros is a transcriptional regulator and an 
important factor implicated in chromatin 
remodeling that can influence hypothalamic-
pituitary cell development, differentiation and 
proliferation (38). 
Genetic alterations  
Despite the pituitary tumors are in 
majority sporadic, they characterized some 
genetic forms of pituitary adenoma in familial 
cases. 
PTTG gene 
The pituitary tumor transforming gene 
(PTTG) is another less well studied marker, 
found in 90% of pituitary tumors. 2.9% or 
more of PTTG expression can be also 
considered an indication of a more aggressive 
behavior of pituitary adenomas.  
Comparing PTTG expression in 54 
pituitary tumors, Zhang et al. found no 
correlation with radiological tumor stage in 
clinically non-functioning adenomas, even 
they founded significantly higher levels in 
invasive tumors (24). 
H-ras gene mutation  
Several proto-oncogenic events, as the p53 
and p27kipl expression, the function of 
telomerase, and the role of H-ras gene 
mutation, can represent central events in the 
pathogenesis and spread of pituitary 
carcinomas (15, 16, 17). 
Galectin-3/ LGALS3 gene 
Galectin-3 is a protein encoded by the 
LGALS3 gene, expressed in pituitary gland by 
both folliculostellate cells and normal 
prolactin (PRL) and adrenocorticotropin 
(ACTH)-producing cells, but not by most 
other cell types. LGALS3 is a useful 
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immunohistochemical marker for 
differentiating silent from functioning ACTH-
subtype adenomas. 
LGALS3 represents a reliable marker for 
predicting the aggressive tumor behavior 
(assessing a high risk of progression or 
recurrence) (12). PRL and ACTH functioning 
pituitary tumors (adenomas and carcinomas) 
are aggressive subtypes of tumors, in which the 
invasive growth with suprasellar extension, a 
high Ki-67 index, and LGALS3 expression 
levels are the most important pathologic 
features, therefore a target therapy against 
Galectin-3 protein may be useful. 
Apoptosis  
Apoptosis, the programmed cell death, is a 
sequence of events characterized by cellular 
shrinkage and nuclear demarcation, which 
ends with the elimination of damaged cells. In 
neoplasms, there is a misbalance between 
mitotic and apoptotic activity, apoptosis is 
generally suppressed and there is an increased 
tumor growth (15).  
Apoptosis may be a useful prognostic 
marker; the expression of anti-apoptotic factor 
BCL2 and proapoptotic factor BAX also 
correlates with apoptotic indices. A lower 
expression of BCL2 was also reported in 
pituitary carcinomas compared with 
adenomas and the non-tumoral pituitary 
gland (27).   
The new classification criteria for atypical 
adenomas 
Until the 1980’s, the classification of 
pituitary tumors included three types, based 
on tinctoriality correlated with the clinical 
disease: acidophilic with acromegaly, 
basophilic with Cushing’s disease, and 
chromophobic adenomas. The advancements 
in electron microscopy (EM) and 
immunohistochemistry (IHC) changed the 
classification of pituitary tumors into five 
immunocytochemical types and a dozen 
ultrastructural subtypes, based on their 
organelles appearance (granulations and 
mitochondria) and their hormonal secretion 
(39). 
The new 2004 WHO classification for 
endocrine tumors define 3 types of pituitary 
tumors: benign adenoma, atypical adenoma, 
and carcinoma (1,8).  
Wolfsberger and Knosp criticized the WHO 
2004 classification; they stated that ‘‘the 
definition of invasiveness is needed and should 
be included in this classification’’ and underline 
the need to also include proliferation, evaluated 
by markers of the cell cycle with well-defined 
thresholds (40). Considering invasion potential 
for atypical adenomas at a threshold of Ki-67 
index >3% and p53 >5%, Saeger et al. found 
only 2.7% of among 241 tumors from the 
German registry (1).  
Actually, it is recognized that there is no 
reliable distinction between carcinoma and 
adenoma based on distinct standard 
histological criteria or electron microscopic 
features, distinct that would permit a reliable 
early prediction of future aggressive behavior 
of a pituitary adenoma, even if invasive.   
Based on above mentioned characteristics 
of atypical adenomas, recently, a new 
clinicopathological classification has been 
proposed, which takes into account tumor 
size, immunocytochemical type (hormonal 
immunoexpression profile), tumoral invasion 
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(invasion to the cavernous and sphenoid 
sinuses, evaluated by magnetic resonance 
imaging (MRI) or histology), and tumor cell 
proliferation markers (Ki-67 and p53) (41). 
Therefore, based on their invasion and 
proliferation characteristics, the tumors were 
classified into five grades: grade 1a: non-
invasive tumor, grade 1b: non-invasive and 
proliferative tumor, grade 2a: invasive tumor, 
grade 2b: invasive and proliferative tumor, 
grade 3: metastatic tumor). 
Trouillas proposed to consider the grade 2b 
tumors with high risk of recurrence as tumors 
suspected of malignancy (41). 
The aggressive subtypes of pituitary 
adenomas  
Aggressive prolactin-secreting pituitary tumors  
Prolactinomas represent about 40% of all 
pituitary adenomas. Two histological subtypes 
are clinically relevant (42):  
1 – the sparsely granulated lactotroph 
adenoma - is the most common form, more 
aggressive in men than in women, which can 
reach considerable size, high PRL serum levels 
and invasive features at MRI. In many cases, 
this type responds dramatically to dopamine 
agonist therapy;  
2 – the densely granulated lactotroph 
adenoma, with diffuse cytoplasmic positivity 
to PRL  -  it is very rare;  
3 – the acidophil stem cell adenomas -  
presents weakly acidophilic cells producing 
PRL and GH, oncocytic changes, and giant 
mitochondria. It often has an aggressive 
clinical behavior, with hyperprolactinemia 
and/or acromegaly (1).   
Clinically, some mass effect features are 
observed, such as visual field restriction or dull 
headache at presentation and symptoms of 
amennorrhea and galactorrhea in females and 
erectile dysfunction in males.   
The aggressive prolactinomas present 
serum PRL levels which can vary widely (6–
21,560 ng/ml in one series). Imagistic studies 
often put into evidence a pituitary 
macroadenoma with invasion of one/both 
cavernous sinuses, which extent and often 
encase the internal carotid arteries (43,44).  
Aggressive corticotroph pituitary tumors 
10–15% of all pituitary adenomas are 
ACTH-secreting adenomas. Two 
morphologic variants have been identified at 
electron microscopy level: subtype 1 - densely 
granulated basophilic tumors, similar to 
functional ACTH secretory tumors and 
subtype 2 - different by electron microscopy, 
chromophobic, sparsely granulated and their 
secretory granules are smaller and irregular in 
shape and lack cytoplasmic intermediate 
filaments (45).The densely granulated 
corticotroph subtype is the most common 
(42,45), usually present in patients with 
Cushing’s disease and Nelson’s syndrome.  
Crooke cell tumors is a rare form of ACTH 
producing adenoma, tumor cells presenting a 
variable but often characteristic Crooke's 
intracytoplasmic accumulation of cytokeratin. 
Clinicopathologically, these tumors represent 
a distinct entity from typical 
endocrinologically active corticotroph 
adenomas; they may produce ACTH-causing 
Cushing’s disease or may be 
endocrinologically silent. Pituitary tumors 
composed of Crooke cells exhibit aggressive 
clinical behavior, with high recurrence rate, 
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and invasiveness (46), and nearly always these 
recurrent invasive macroadenomas may 
progress to corticotroph carcinomas (46). The 
Crooke’s cell adenoma must not be confused 
with keratin deposition in the normal 
corticotrophs (Crookes hyaline change), first 
described in 1935 by endocrinologist AC 
Crooke. 
Clinically, patients with aggressive 
pituitary corticotroph tumors present 
Cushing’s disease, with ACTH dependent 
hypercortisolism, including central obesity, 
rounded facies, abdominal and proximal limb 
striae, hypertension, altered menses, 
osteoporosis and delayed wound healing (40). 
A second clinical onset is observed in 
Nelson’s syndrome, the rapid enlargement 
(likely to occur within the first 3 years) of a 
pre-existing ACTH-secreting pituitary 
adenoma that occurs after bilateral 
adrenalectomy to control hypercortisolismin 
patients with Cushing’s disease (47).  
Thirdly, they are recurrent but ’’silent’’ 
corticotroph tumors, which present variable 
immunopositivity for ACTH. Clinically, are 
nonfunctional adenomas, which do not secrete 
excess ACTH, but have a more aggressive 
course than most functional ACTH-secreting 
tumors (48) and recur more frequently than 
tumors with hypercortisolism (48). 
Aggressive growth-hormone secreting pituitary 
tumors  
GH-secreting adenomas represent 10–15% 
of all pituitary adenomas and are classified 
into five histological subtypes; the more 
common are densely and sparsely granulated 
somatotroph adenomas (42).      
Usually, these adenomas are small or 
medium in size, and GH serum levels are 
moderate increased; they respond to treatment 
with long-acting somatostatin analogs. 
Quantification of somatostatin receptors 2 and 
5 (SSTR2, SSTR5) can be useful to predict the 
response to medical treatment (49): all tumors 
(GH, TSH, ACTH, and FSH-LH secreting) 
with a low SSTR2 expression are at a higher 
risk of resistance to octreotide / lanreotide and 
those with high SSTR5R expression are more 
likely to respond to pasireotide treatment. This 
detection is always negative in PRL tumors 
(49). 
The sparsely granulated somatotroph 
adenomas are larger and more invasive 
(proved by MRI); this lead to an incomplete 
resection and in some cases, they are resistant 
to long-acting somatostatin analog therapy 
(50).   
Aggressive gonadotroph and thyrotroph 
pituitary tumors 
Almost all pituitary tumors (up to 97 % in 
some studies) are immunohistochemical 
positive for the FSH and/or LH 
gonadotrophins, even 30–35 % of them are 
clinically nonfunctioning (do not cause a 
clinical endocrine syndrome). Often those 
tumors are large invasive macroadenomas, 
with pressure on the optic chiasm, varying 
degrees of hypopituitarism; and FSH and LH 
serum levels which may be elevated or not 
(51). The clinically nonfunctioning tumors are 
rarely encountered as aggressive tumors, but 
can behave aggressively and they were 
reported cases of clinically nonfunctioning 
pituitary carcinoma.  
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The oncocytomas are FSH-LH adenomas 
with high concentration of mitochondria. 
The null cell adenomas are tumors 
immunonegatives for 
adenohypohysialhormones, they represent 
only 1% from all pituitary tumors.  
TSH-producing adenomas are less than 2% 
of all pituitary adenomas (1, 42, 45). 
Aggressive plurihormonal tumors  
The silent subtype 3 adenomas are 
plurihormonal tumors, usually 
immunohistochemical positive for GH, PRL 
and TSH, with nuclear inclusions called 
spheridia (electron microscopy revealed). 
Clinically, they are usually silent, but may be 
associated with hyperprolactinemia, 
acromegaly or hyperthyroidism. These tumors 
can also have an aggressive behavior (52).  
Conclusions 
For pituitary gland, it would be more 
correctly from oncological point of view 
(adenoma means benign) to use instead of 
“atypical” or ”aggressive” adenoma, the term 
“tumor suspected of malignancy” (tumor 
grade 2b). 
There is not a single specific biomarker 
able to confidently predict the 
aggressive/invasive behavior for pituitary 
tumors.   
The correct histological diagnosis of 
pituitary adenomas may identify adenomas’ 
subtypes known as having an aggressive 
clinical behavior: sparsely granulated 
somatotroph, acidophil stem cell, 
silentcorticotroph, with Crooke’s cell, 
thyrotroph or silent subtype 3. 
There is hope that establishing specific 
biological markers for invasive process, would 
became possible an early diagnosis and 
prevention of invasive pituitary adenomas.  
Because aggressive pituitary tumors are 
difficult to manage, generally unresponsive to 
therapy, tend to recur quickly and are 
associated with poor prognosis, the early 
diagnosis and the search of new therapeutic 
approaches is becoming mandatory. 
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